title: Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma.
authors.affiliation: The Department of Medicine and the Knight Cancer Institute at Oregon Health & Science University, the University of Pennsylvania, PN, USA scottem@ohsu.edu.
authors.forename: Emma C
authors.initials: EC
authors.lastname: Scott
authors.affiliation: The Department of Medicine and the Knight Cancer Institute at Oregon Health & Science University, the University of Pennsylvania, PN, USA.
authors.forename: Richard T
authors.initials: RT
authors.lastname: Maziarz
authors.affiliation: The Department of Medicine and the Knight Cancer Institute at Oregon Health & Science University, the University of Pennsylvania, PN, USA.
authors.forename: Stephen E
authors.initials: SE
authors.lastname: Spurgeon
authors.affiliation: The Department of Medicine and the Knight Cancer Institute at Oregon Health & Science University, the University of Pennsylvania, PN, USA.
authors.forename: Eva
authors.initials: E
authors.lastname: Medvedova
authors.affiliation: The Department of Medicine and the Knight Cancer Institute at Oregon Health & Science University, the University of Pennsylvania, PN, USA.
authors.forename: James
authors.initials: J
authors.lastname: Gajewski
authors.affiliation: The Department of Medicine and the Knight Cancer Institute at Oregon Health & Science University, the University of Pennsylvania, PN, USA.
authors.forename: Shara
authors.initials: S
authors.lastname: Reasor-Heard
authors.affiliation: Public Health and Preventative Medicine, Oregon Health & Science University, the University of Pennsylvania, PN, USA.
authors.forename: Byung
authors.initials: B
authors.lastname: Park
authors.affiliation: The Department of Medicine and the Knight Cancer Institute at Oregon Health & Science University, the University of Pennsylvania, PN, USA.
authors.forename: Anne
authors.initials: A
authors.lastname: Kratz
authors.affiliation: The Department of Pathology and Laboratory Medicine and the Knight Cancer Institute at Oregon Health & Science University, the University of Pennsylvania, PN, USA.
authors.forename: George V
authors.initials: GV
authors.lastname: Thomas
authors.affiliation: The Department of Pathology and Laboratory Medicine and the Knight Cancer Institute at Oregon Health & Science University, the University of Pennsylvania, PN, USA.
authors.forename: Marc
authors.initials: M
authors.lastname: Loriaux
authors.affiliation: The Department of Pathology and Laboratory Medicine and the Knight Cancer Institute at Oregon Health & Science University, the University of Pennsylvania, PN, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Cascio
authors.affiliation: The Department of Pathology and Laboratory Medicine and the Knight Cancer Institute at Oregon Health & Science University, the University of Pennsylvania, PN, USA.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Podolak
authors.affiliation: The Department of Medicine and the Knight Cancer Institute at Oregon Health & Science University, the University of Pennsylvania, PN, USA.
authors.forename: Miranda
authors.initials: M
authors.lastname: Gordon
authors.affiliation: The Department of Medicine and the Knight Cancer Institute at Oregon Health & Science University, the University of Pennsylvania, PN, USA.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Botelho
authors.affiliation: Department of Medicine and the Abramson Cancer Center, the University of Pennsylvania, PN, USA.
authors.forename: Edward
authors.initials: E
authors.lastname: Stadtmauer
authors.affiliation: Department of Medicine and the Abramson Cancer Center, the University of Pennsylvania, PN, USA.
authors.forename: Ravi
authors.initials: R
authors.lastname: Amaravadi
authors.affiliation: Department of Medicine and the Abramson Cancer Center, the University of Pennsylvania, PN, USA.
authors.forename: Dan T
authors.initials: DT
authors.lastname: Vogl
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001343:Autophagy / Q000187:drug effects*; D001853:Bone Marrow / Q000473:pathology; D045744:Cell Line, Tumor; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D006886:Hydroxychloroquine / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D012008:Recurrence; D015398:Signal Transduction / Q000187:drug effects; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D047428:Protein Kinase Inhibitors; D006886:Hydroxychloroquine; D058570:TOR Serine-Threonine Kinases